Cash
Sutro discards CEO, 50% of staff, sole clinical-stage ADC and manufacturing site to save cash
Sutro, therapeutic autologous dendritic cells, Changing, CEO, Cash
Bluebird Bio Confronts Financial Crunch Amidst Breakeven Projections
Bluebird Bio, cash gap, breakeven point, financial stability, gene therapy, cash flow
Compass Pathways Delays Phase 3 Psilocybin Trials, Cuts 30% of Workforce to Conserve Cash
Compass Pathways, psilocybin trials, Phase 3 delays, workforce reduction, cash conservation, psychedelic drug development